Kuros Biosciences Launches MagnetOs MIS Delivery System with First Successful US Spine Surgery

Kuros Biosciences' New MagnetOs MIS Delivery System

Announcement

Kuros Biosciences, a known innovator of biologic technologies, completed its first-ever US international case with its new magnetos MIS delivery system. A system features, prefilled, sterile, and single-use delivery system helpful for minimally invasive surgery (MIS), mainly in spine procedures. Considering FDA 510 (k) clearance of the magnetos MIS delivery system in May month this first completion of a case is an additional star to the constellation of milestones in extensive surgeon access to a broader approach for graft delivery.

MagnetOs MIS Foundation

MagnetOs MIS is based on the science of magnetos and its proprietary needle-grip submicron surface technology. It supports the immune system and bolsters bone growth. It is designed for accurate delivery, forecasting contrast outcomes, and surgical efficiency. In comparison to magnetos deliverable in traditional-based systems, the magnetos MIS gained graft placement 3x quickly, improving time in the operating setting.

The MIS system is empowered by the powerful published clinical proof for magnetos in cases where surgical site availability and minimally invasive procedures are important. In a retrospective study, the magnetos gained up to 94.4% fusion rate in 36-level patients treated during open transforaminal lumbar interbody fusions (TLIF) and MIS. Under this scenario, the number of patients detected comorbidities like smoking, diabetes, old spine surgery, and obesity is detected. These results are declared on the basis of previously showcased level 1 controlled prospective clinical data that elaborates magnetos' achievement of close to twice for fusion rate of autograft in posterolateral fusion (79% vs 47%).

Along with the recent ANVISA clearance of magnetos granules, the company also introduced magnetos putty’s approval by the Brazilian regulatory authority. Additionally, this will expand the company’s footprint into the South American orthopedic and spine market. This milestone highlights the elevated demand for magnetos as a clinically proven, safe, and predictable bone grafting alternative.

Statements by Professionals and Industry Leaders

The orthopedic spine surgeon who completed his first case with the new FDA-approved system in Southfield, Michigan, Dr. Daniel Park, said, “Magnetos MIS worked smoothly and precisely as a graft placement in a most challenging MIS TLIF case without any thawing or preparation. It enabled quick and efficient operation.”

CEO of Kuros Biosciences, Chris Fair, said, “We are providing the best to the surgeons' concern over speed, proven outcome, and precision while optimizing MIS techniques, which is in high demand. This will open access to the growth of the us MIS spine segment.”